Brief: Axcella Announces Axa1125’S Ind Clearance For The Treatment Of Nash
13/04/2021 12:45
April 13 (Reuters) - Axcella Health Inc AXLA.O :
* AXCELLA ANNOUNCES AXA1125’S IND CLEARANCE FOR THE
TREATMENT OF
NASH
* AXCELLA HEALTH INC - PHASE 2B CLINICAL TRIAL IN ADULTS
EXPECTED
TO BEGIN IN Q2
Source text for Eikon: ID:nBw6w8rlJa
Further company coverage: AXLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Axcella Health
See all newsAxcella Health Inc expected to post a loss of $1.25 a share - Earnings Preview
Brief: Axcella Health Inc- On Oct 4, Co Received Notice From Nasdaq That Co Had Regained Compliance With Nasdaq
Brief: Axcella Announces Reverse Stock Split Effective September 19, 2023
U.S. STOCKS ON THE MOVE-PDD Holdings, Catalent, Best Buy
Brief: Axcella Granted Patent For Long Covid Fatigue Treatment